FINWIRES · TerminalLIVE
FINWIRES

$SNDA

7 stories mentioning SNDA

Every FINWIRES story that references SNDA, newest first.

Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks advanced late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each rising about 2%.The iShares Biotechnology ETF (IBB) increased 1.2%.In sector news, President Donald Trump said Tuesday that US Food and Drug Administration Commissioner Marty Makary is resigning, Bloomberg reported.In corporate news, West Pharmaceutical Services (WST) shares were down 3% after the company said in a regulatory filing its global operations were disrupted by a cyberattack.Alkermes (ALKS) shares jumped past 7% after the firm said Tuesday a late-stage trial of Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and secondary targets.Sonida Senior Living's (SNDA) recent stock decline was unwarranted given the broad-based strength in its Q1 results, RBC said in a note. RBC kept its outperform rating and raised its price target to $45 from $39. Shares eased 0.2%.Dr. Reddy's Laboratories (RDY) plans to launch a generic version of Novo Nordisk's (NVO) Ozempic this month in Canada, Bloomberg reported Tuesday, citing Chief Executive Erez Israeli. Dr. Reddy's shares fell 5.3%, and Novo rose 1.1%.

$ALKS$NVO$RDY$SNDA$WST
Sectors

Sector Update: Healthcare Stocks Gain in Afternoon Trading

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) climbing 2.2%.The iShares Biotechnology ETF (IBB) increased 1.4%.In corporate news, Alkermes (ALKS) shares jumped past 5% after it said Tuesday a late-stage trial evaluating its investigational Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and key secondary endpoints.Sonida Senior Living's (SNDA) recent stock decline was unwarranted given the broad-based strength in its Q1 results, RBC Capital Markets said in a note. RBC reiterated its outperform rating on the stock and raised its price target to $45 per share from $39. Sonida shares added 1.5%.Agios Pharmaceuticals (AGIO) shares rose 1% after it said Tuesday it has submitted a supplemental New Drug Application to the US Food and Drug Administration seeking accelerated approval of mitapivat for the treatment of sickle cell disease.

$AGIO$ALKS$SNDA
Wire

Sonida Senior Living Stock Decline Unwarranted Given Business Momentum, RBC Says

Sonida Senior Living's (SNDA) recent stock decline was unwarranted given the broad-based strength in its Q1 results, RBC Capital Markets said in a Monday research report.Robust costs controls driven by labor productivity gains, scheduling discipline, and real-time KPI dashboards are driving margin expansion, the analysts said.A stable cost structure combined with growing occupancy offers a compelling setup for incremental margins in the future, according to the note.The company's $16 million to $20 million year-one general and administrative expenses synergy target related to its merger with CNL Healthcare Properties remains on track, RBC said.RBC reiterated its outperform rating on the stock and boosted its price target to $45 per share from $39.Price: $37.57, Change: $+0.60, Percent Change: +1.64%

$SNDA
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Healthcare Select Sector SPDR ETF (XLV) declining 0.4%.The iShares Biotechnology ETF (IBB) was little changed.In corporate news, Zoetis (ZTS) shares fell 7.5% after BNP Paribas cut its price target to $146 from $185, following the company's Q1 results late last week.Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 3.7%.Sonida Senior Living (SNDA) shares fell 3.3% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered into a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3%.

$ERAS$MRNA$SNDA$ZTS
Sectors

Sector Update: Healthcare Stocks Mixed in Afternoon Trading

Healthcare stocks were mixed Monday afternoon with the NYSE Healthcare Index rising 0.2% and the State Street Healthcare Select Sector SPDR ETF (XLV) little changed, paring earlier losses.The iShares Biotechnology ETF (IBB) increased 0.3%.In corporate news, Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 2.2%.Sonida Senior Living (SNDA) shares fell 3.6% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Three analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3.3%, and Merck added 1.2%.

$ERAS$MRK$MRNA$SNDA
Sectors

Sector Update: Health Care

Healthcare stocks declined Monday afternoon, with the NYSE Healthcare Index fractionally lower and the State Street Healthcare Select Sector SPDR ETF (XLV) down 0.2%.The iShares Biotechnology ETF (IBB) increased 0.4%.In corporate news, Sonida Senior Living (SNDA) shares fell 3.3% after it reported Q1 loss Monday of $2.39 per diluted share, wider than a loss of $0.77 a year earlier. Three analysts polled by FactSet expected a loss of $1.53.

$SNDA
Research

Cantor Fitzgerald Initiates Coverage on Sonida Senior Living With Overweight Rating, $36 Price Target

Sonida Senior Living (SNDA) has an average rating of overweight and mean price target of $35.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SNDA